<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>HIV-associated <z:hpo ids='HP_0005523'>lymphoproliferative disorders</z:hpo> represent a <z:hpo ids='HP_0001425'>heterogeneous</z:hpo> group of diseases, arising in the presence of HIV-associated <z:hpo ids='HP_0002721'>immunodeficiency</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>The overall prevalence of HIV-associated <z:hpo ids='HP_0002665'>lymphoma</z:hpo> is significantly higher compared to that of the general population and it continues to be relevant even after the wide availability of highly active antiretroviral therapy (HAART) (1) </plain></SENT>
<SENT sid="2" pm="."><plain>Moreover, they still represent one of the most frequent cause of <z:hpo ids='HP_0011420'>death</z:hpo> in HIV-infected patients </plain></SENT>
<SENT sid="3" pm="."><plain>Epstein-Barr virus (EBV), a Î³-Herpesviruses, is involved in human <z:e sem="disease" ids="C0598766" disease_type="Neoplastic Process" abbrv="">lymphomagenesis</z:e>, particularly in HIV immunocompromised patients </plain></SENT>
<SENT sid="4" pm="."><plain>It has been largely implicated in the development of B-cell <z:hpo ids='HP_0005523'>lymphoproliferative disorders</z:hpo> as Burkitt <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>), <z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">Hodgkin disease</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HD</z:e>), systemic non Hodgkin <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (NHL), primary central <z:mp ids='MP_0008912'>nervous</z:mp> system <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (PCNSL), nasopharyngeal <z:mp ids='MP_0002038'>carcinoma</z:mp> (NC) </plain></SENT>
<SENT sid="5" pm="."><plain>Virus-associated <z:hpo ids='HP_0002665'>lymphomas</z:hpo> are becoming of significant concern for the mortality of long-lived HIV immunocompromised patients, and therefore, research of advanced strategies for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AIDS</z:e>-related <z:hpo ids='HP_0002665'>lymphomas</z:hpo> is an important field in <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> chemotherapy </plain></SENT>
<SENT sid="6" pm="."><plain>Detailed understanding of the EBV lifecycle and related <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> at the molecular level is required for novel strategies of molecular-targeted <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> chemotherapy The linkage of HIV-related <z:hpo ids='HP_0002665'>lymphoma</z:hpo> with <z:e sem="disease" ids="C0149678" disease_type="Disease or Syndrome" abbrv="">EBV infection</z:e> of the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> clone has several pathogenetic, prognostic and possibly therapeutic implications which are reviewed herein </plain></SENT>
</text></document>